Compare American States Water Company (AWR) vs Mesoblast Limited (MESO) Price & Performance

AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.

Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.